What does Castle Biosciences do?
Castle Biosciences, Inc. is a U.S.-focused molecular diagnostics company listed on Nasdaq under CSTL. It develops laboratory-developed tests that use gene expression, spatial biology, protein markers and algorithmic analysis to answer questions that conventional staging or pathology may not resolve well enough. The company describes its mission as improving health through innovative tests that guide patient care, a useful summary because Castle is not selling laboratory equipment: it sells clinically actionable information generated from patient samples. Its official company overview emphasizes dermatology and gastroenterology, while its commercial portfolio also includes uveal melanoma and a newly launched atopic dermatitis therapy-guidance test.
Which clinical questions define the portfolio?
The most important distinction is between diagnosis, prognosis and therapy guidance. MyPath assists diagnosis; DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher and DecisionDx-UM mainly stratify future risk; AdvanceAD-Tx is intended to inform which systemic treatment pathway may fit a patient’s biology. Castle’s DecisionDx-Melanoma overview shows why this matters: the output supplements clinicopathologic staging with an individualized biological risk estimate rather than replacing physician judgment.
How does Castle Biosciences make money?
Castle earns revenue when it completes and delivers test reports. A clinician orders a test, the laboratory receives and processes the sample, proprietary assays and algorithms generate a result, and Castle bills government payors, commercial insurers, laboratory intermediaries or, in limited cases, patients. Revenue recognition does not necessarily occur in the same quarter as the report because the amount collectible can remain variable until payment experience or a payor decision becomes sufficiently clear.
Why reimbursement matters more than list price
The economic engine is test volume multiplied by realized average selling price, not simply the published laboratory fee. Coverage policy, medical necessity criteria, coding, claim acceptance, appeals, sequestration and commercial contracts all influence realized revenue. The latest Form 10-Q for the quarter ended March 31, 2026 reported the following 2026 Medicare rates before applicable sequestration:
| Test | 2026 Medicare rate | Commercial meaning |
|---|---|---|
| DecisionDx-Melanoma | $7,193 | High-value core test with established ADLT status and Medicare coverage criteria. |
| TissueCypher | $4,950 | Fast-growing gastroenterology product; volume expansion has become the primary diversification driver. |
| MyPath Melanoma | $1,950 | Lower-price diagnostic adjunct for ambiguous lesions. |
| DecisionDx-UM | $7,776 | Small-volume niche test with an attractive per-report rate. |
Which products now drive Castle’s revenue and volume?
Castle reports one operating segment, but it disaggregates revenue between dermatologic and non-dermatologic tests. That mix changed sharply in the first quarter of 2026. Dermatologic revenue was $41.1 million, while non-dermatologic revenue was $42.6 million. Non-dermatologic tests therefore represented 50.9% of quarterly revenue, up from 28.4% one year earlier. TissueCypher was the main reason, while DecisionDx-SCC reimbursement pressure pulled the dermatology category lower.
What do report volumes reveal?
DecisionDx-Melanoma remains the highest-value foundational franchise: reports rose 16% year over year to 10,021. TissueCypher grew 58% to 11,745 and has since surpassed 100,000 cumulative clinical orders, according to Castle’s June 2026 milestone announcement. DecisionDx-SCC reports declined 15% to 3,702; MyPath rose 5% to 973; and DecisionDx-UM rose 5% to 492. The product-level lesson is that volume, price and reimbursement must be analyzed together.
Where does the next growth option sit?
AdvanceAD-Tx is the most material new option. It evaluates 487 genes across 12 inflammatory and skin-related pathways to classify moderate-to-severe atopic dermatitis patients into molecular profiles relevant to systemic therapy selection. Castle received about 650 orders during Q1 2026 while access was still limited, and New York State approved the assay in July 2026. The New York approval announcement removes a geographic commercialization constraint, but reimbursement, evidence development and physician behavior will determine whether the large stated addressable market converts into revenue.
What does Castle Biosciences’ latest quarter show?
The official first-quarter 2026 earnings release shows a business in transition rather than a simple contraction. Revenue fell because the DecisionDx-SCC coverage loss and the May 2025 discontinuation of IDgenetix removed revenue that existed in the comparison quarter. Meanwhile, the two core growth products—DecisionDx-Melanoma and TissueCypher—grew combined reports by 36%.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $83.7M | $88.0M | Down 4.9%; dermatology pressure outweighed GI growth. |
| Gross profit / margin | $60.9M / 72.8% | $43.3M / 49.2% | Prior year included accelerated IDgenetix intangible amortization. |
| Operating loss | $(18.4)M | $(27.9)M | Improved despite higher R&D and SG&A. |
| Net loss / diluted EPS | $(14.5)M / $(0.49) | $(25.8)M / $(0.90) | Loss narrowed, helped by lower amortization and equity-security gains. |
| Operating cash flow | $(22.1)M | $(6.0)M | Included $28.8M of annual bonuses and health-benefit payments not expected to recur in 2026. |
| Adjusted EBITDA | $(5.1)M | $13.0M | Current operating investment remains ahead of near-term revenue conversion. |
Is the top-line decline masking adoption growth?
Yes, but only partially. Total report volume rose 10% to 26,933, and the core pair grew 36%. However, a test report does not equal recognized revenue, and the product mix shifted toward TissueCypher’s lower Medicare rate relative to DecisionDx-Melanoma. Castle raised full-year 2026 revenue guidance to $345–355 million, implying roughly flat-to-3% growth from 2025’s $344.2 million. Achieving the range requires sustained core volumes and no material deterioration in realized pricing or collections.
What strategic turning points still shape Castle today?
Castle’s history is best understood as a sequence of evidence-building, reimbursement milestones and portfolio transactions. The company has used acquisitions to enter adjacent clinical markets, but the outcomes have been uneven. TissueCypher became a major growth engine; IDgenetix was discontinued after three years. That contrast is central to evaluating management’s capital allocation.
-
2007Derek Maetzold founded Castle and became CEO. Founder continuity still shapes a long-duration evidence and commercialization strategy.
-
2009Castle licensed uveal-melanoma intellectual property from Washington University and introduced DecisionDx-UM, establishing the laboratory-developed-test model.
-
2019The company completed its Nasdaq IPO, creating public-market funding and a liquid acquisition currency.
-
2021Castle acquired the Myriad MyPath laboratory and Cernostics. MyPath added diagnostic melanoma testing; Cernostics brought TissueCypher and the GI franchise.
-
2022The AltheaDx acquisition added IDgenetix, expanding beyond cancer but introducing integration and commercial-execution risk.
-
2025Castle discontinued IDgenetix, acquired Previse for $18.7M including transaction costs, and launched AdvanceAD-Tx on limited access. It simultaneously narrowed and broadened the portfolio.
-
2026TissueCypher passed 100,000 cumulative orders and AdvanceAD-Tx obtained New York assay approval, reinforcing GI scale and opening a new dermatology therapy-guidance pathway.
What did the acquisition record teach?
The 2025 Form 10-K shows both sides. TissueCypher reports reached 39,014 in 2025, up 86%, validating the strategic logic of acquiring Cernostics. By contrast, Castle fully accelerated the remaining amortization of IDgenetix technology and discontinued the offering in May 2025; the commercial milestones tied to up to $75 million of additional consideration were not achieved. Students should view Castle as an organic-commercialization company with an acquisition overlay, not as a serial acquirer with uniformly repeatable integration economics.
What gives Castle Biosciences a competitive advantage?
Castle’s moat is not a single patent or brand. It is a system of clinical evidence, proprietary assay design, laboratory operations, direct specialist relationships, reimbursement experience and accumulated samples and data. The strongest asset is DecisionDx-Melanoma’s evidence base: the 2025 filing cited 58 peer-reviewed articles supporting clinical validity, clinical utility and outcomes impact. A large publication record can reduce physician uncertainty and make it harder for a new entrant to match adoption quickly.
Who competes with Castle?
| Castle product | Principal alternative or rival | Castle’s positioning | Competitive pressure |
|---|---|---|---|
| DecisionDx-Melanoma | Traditional staging; SkylineDx | Integrated biological and clinicopathologic risk; broad evidence base. | Guideline acceptance and clinician willingness to change established practice. |
| TissueCypher | Traditional pathology; Interpace Diagnostics; potential GERD-screening entrants such as Lucid Diagnostics | Spatialomics-based progression risk layered onto routine biopsy material. | Clinical-society recommendations, workflow adoption and future competing prognostic tests. |
| DecisionDx-SCC | Traditional clinical and pathology staging | Risk of metastasis plus predicted radiation-response information. | Coverage, not direct product competition, is presently the larger constraint. |
| DecisionDx-UM | LabCorp subsidiary and academic laboratories | Longstanding specialist adoption and a defined risk-classification workflow. | Small market size limits growth even with a strong position. |
Why is the moat still contestable?
Because physicians order tests but payors fund them, insurers retain substantial bargaining power. Traditional pathology is an entrenched substitute without an incremental molecular-test bill. Castle must continually publish evidence, educate specialists and defend coverage. Its CLIA-certified, CAP-accredited laboratories can serve all 50 states, although some reagents and instruments have sole suppliers. The moat is therefore valuable but reimbursement-dependent.
How financially strong is Castle Biosciences?
Castle has a strong liquidity position relative to its debt, but recurring GAAP profitability is not yet established. At March 31, 2026, cash and cash equivalents were $63.8 million and marketable securities were $197.9 million, totaling $261.7 million. Net debt was therefore deeply negative against $10.1 million of debt. Current assets of $328.9 million exceeded current liabilities of $48.8 million by about $280.1 million.
What did FY2025 say about cash conversion?
FY2025 cash generation exceeded the $24.2 million GAAP net loss partly because depreciation, amortization and $45.9 million of stock-based compensation were non-cash. That conversion still warrants caution: equity compensation dilutes owners, and $36.0 million of property purchases included headquarters investment. Q1 2026 used $22.1 million of operating cash plus $12.5 million of capex, implying about $34.6 million of negative simple free cash flow.
| Financial signal | FY2025 | Q1 2026 | Research interpretation |
|---|---|---|---|
| Revenue | $344.2M | $83.7M | Annual growth slowed to 3.7%; quarterly comparison absorbed portfolio and coverage changes. |
| GAAP gross margin | 69.2% | 72.8% | Amortization makes comparisons noisy; adjusted laboratory economics are stronger than the 2025 GAAP margin suggests. |
| R&D expense | $51.9M | $14.4M | Evidence generation and pipeline development are essential reinvestment, not optional overhead. |
| SG&A expense | $229.3M | $64.9M | Direct commercialization is expensive; operating leverage depends on scaling test volume faster than selling costs. |
| Net income / loss | $(24.2)M | $(14.5)M | Profitability remains sensitive to reimbursement, amortization and growth spending. |
| Liquidity | $299.5M | $261.7M | Substantial runway, but Q1 seasonal payments and capex reduced the balance. |
Who owns Castle Biosciences stock, and how is it governed?
Castle has one common-share class with one vote per share, rather than a founder-controlled dual-class structure. Founder and CEO Derek Maetzold nevertheless remains influential through his operating role, board seat and 2.7% beneficial ownership. The investor base mixes passive institutions with specialist healthcare funds.
| Holder or group | Beneficial shares | Ownership | Why it matters |
|---|---|---|---|
| BlackRock | 2,338,005 | 7.7% | Largest disclosed holder; mainly institutional governance influence rather than operational control. |
| RTW Investments | 2,115,237 | 7.0% | Healthcare-specialist capital can scrutinize pipeline economics and evidence quality closely. |
| Vanguard | 1,832,535 | 6.0% | Passive ownership reinforces standard governance and disclosure expectations. |
| Principal Financial Group | 1,585,639 | 5.3% | Another meaningful institution in a dispersed ownership structure. |
| Portolan Capital Management | 1,611,099 | 5.2% | Active small- and mid-cap ownership may increase focus on execution and capital efficiency. |
| All directors and executive officers | 1,929,804 | 6.1% | Meaningful alignment, though not enough to control a vote. |
Ownership figures are from Castle’s 2026 definitive proxy statement, based on 30,290,086 shares outstanding on March 20, 2026. The proxy reported eight directors, seven of whom were independent. The board is classified into three staggered classes, which supports continuity but also makes rapid board replacement more difficult.
What do incentives signal?
The 2025 bonus framework assigned revenue a 75% target weighting and also included product updates, electronic-medical-record integration and DecisionDx-SCC reimbursement progress. Researchers should still compare revenue incentives with collection quality, cash flow and dilution, because commercial expansion can precede proven economic returns.
Which opportunities, risks and KPIs matter most?
Castle’s opportunity set is asymmetric. DecisionDx-Melanoma and TissueCypher already have adoption and reimbursement, while AdvanceAD-Tx could enter a much larger market. The central risk is slower evidence acceptance by payors, guidelines or clinicians than Castle’s spending plans assume.
What could change the outlook most sharply?
| Factor | Opportunity | Risk | Financial line affected |
|---|---|---|---|
| Reimbursement | Broader commercial coverage and favorable DecisionDx-SCC reconsideration. | Coverage withdrawal, lower rates, denials, audits or recoupments. | Revenue, accounts receivable, cash collections and gross margin. |
| Clinical evidence and guidelines | Prospective utility data can accelerate specialist adoption. | Contradictory studies or exclusion from guidelines can slow ordering. | Test volume, sales productivity and R&D requirements. |
| AdvanceAD-Tx launch | Therapy guidance in a large atopic dermatitis population. | Low paid conversion, slow reimbursement or weak repeat use. | Future revenue, SG&A leverage and pipeline return. |
| Acquisitions and partnerships | Previse assets may broaden GI testing and sampling methods. | Integration failure, impairment or another IDgenetix-style exit. | Cash, intangible assets, amortization and operating expense. |
| Laboratory and suppliers | Dual-site capacity supports scale and business continuity. | Sole-source reagent or equipment disruption and sample-handling errors. | Cost of sales, turnaround time, reputation and volume. |
| Regulation and data | High-quality compliance can reinforce trust and barriers to entry. | Changing laboratory-test oversight, privacy rules or cybersecurity events. | Compliance cost, launch timing and potential liabilities. |
Why does Castle Biosciences matter for valuation?
A DCF should model each product separately by volume, realized price, coverage and selling cost. DecisionDx-Melanoma is the mature anchor, TissueCypher the scale driver, DecisionDx-SCC a coverage-sensitive option and AdvanceAD-Tx an early launch with a wide outcome range. Portfolio exits and intangible amortization reduce historical margin comparability.
| Valuation driver | Base analytical question | Upside mechanism | Downside mechanism |
|---|---|---|---|
| Core report growth | Can DecisionDx-Melanoma and TissueCypher sustain double-digit adoption? | Higher clinician penetration and repeat ordering. | Maturing territories or guideline resistance. |
| Realized reimbursement | How close are collections to published or contracted rates? | Broader coverage and fewer denials. | Rate cuts, noncoverage or recoupments. |
| Commercial leverage | Can SG&A grow slower than revenue? | More reports per sales representative and shared dermatology relationships. | New-product teams added before demand materializes. |
| Pipeline value | What probability and timing should be assigned to AdvanceAD-Tx? | Rapid paid adoption after access and evidence milestones. | Low conversion or prolonged reimbursement investment. |
| Reinvestment and dilution | How much cash and equity compensation are required to support growth? | Existing liquidity funds expansion without major external capital. | Persistent losses and stock awards reduce per-share value. |
| Terminal risk | How durable are evidence, patents, coverage and clinician behavior? | Tests become embedded in care pathways. | New technology, regulation or payor policy compresses economics. |
Which margin should a model use?
Acquisition amortization can distort GAAP gross margin, while adjusted margin better reflects laboratory service economics. A DCF must still include recurring evidence, selling, billing, technology and compliance costs. The decisive test is whether gross profit dollars grow faster than SG&A and R&D while collections remain sound.
What is the key takeaway from Castle Biosciences analysis?
Castle matters because it has built a scaled, specialist molecular-diagnostics platform around clinically actionable tests rather than broad commodity laboratory services. DecisionDx-Melanoma provides the evidence-rich anchor, while TissueCypher has become a genuine second growth engine and shifted the revenue mix toward gastroenterology. The balance sheet is strong enough to support continued clinical studies and commercialization, and founder-led strategic continuity can be valuable in a market where evidence and reimbursement develop over many years.
The tension is that scientific adoption and economic monetization are different achievements. DecisionDx-SCC showed how one Medicare coverage decision can reduce revenue despite continued test activity. IDgenetix showed that an acquired product can fail to earn its commercial investment. AdvanceAD-Tx now tests whether Castle can repeat the successful TissueCypher playbook—evidence, access, reimbursement and direct specialist adoption—without another expensive detour.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.